SOLUTION
Telling a bigger story
Announcing Unlearn’s Series C round only a few weeks after kicking off the program, the Unlearn and PAN teams immediately synced to ensure the announcement went off without a hitch. They worked together to develop focused messaging around the funding, using it as an opportunity to tell the bigger story of how Unlearn is advancing AI to eliminate trial and error in medicine with its novel digital twins.
pieces of overall coverage
Result
Reaching core audiences
The round secured high-impact, quality coverage that highlighted how Unlearn’s unique AI model can speed up clinical research. The team secured 39 total pieces of coverage across pharmaceutical audiences, including in top tier publications such as Axios, Bloomberg, and the Wall Street Journal. In addition, coverage appeared in core trades such as Fierce Biotech, Clinical Trials Arena, Modern Healthcare, as well as local publications.
pieces of business press coverage
The chance to tell an impactful funding story is a personal favorite, especially for a company that is truly making a difference in an industry that needs it. Unlearn is changing the way clinical research is done – a facet of healthcare that is historically behind the times.”
Alyssa Horowitz, Senior Account Supervisor at PAN
